The MPS, which combines an inflammatory marker and serum albumin, offers a comprehensive assessment of both nutritional status and inflammation, exhibiting a good performance as an independent prognostic index in mPDAC and in advanced GC. This evidence concerns the gene ALB and gastric cancer.